Orphan Drugs & Rare Diseases 2017

San Francisco, CA

The global orphan drugs market is expected to grow at a steady CAGR of 11.43% from 2016 to 2022. At the current forecasted growth rate, the orphan drugs market is expected to grow from USD 111.87 billion in 2016 and become worth USD 214.14 billion by 2022.


The growth of the global orphan drugs market is increasing due to the growing rare diseases. Orphan diseases are rare in nature which means its occurrence rate is very low, but its prevalence rate is expected to increase in the forecasted period thereby increasing the demand of global orphan diseases market. There are around 7000 rare types of rare diseases and disorders, these numbers are increasing day by day. 80% of rare diseases are genetically originated and rest are result of infections, environmental causes and allergies. Around 50% of genetic diseases are in children’s, 30 % of children with rare diseases cannot live for more than 5 years. Rare diseases are one of the life-threatening diseases that kills millions of lives worldwide. Orphan drugs are the pharmaceutical agent that is specially developed for rare diseases. The prevalence rate of rare diseases are growing at a faster rate, the result in growing need of drugs to cure that diseases.


Paradigm Global Events is again proud to present our bi-annual Orphan Drugs & Rare Diseases Global Congress 2017 Americas. The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialisation, policies, reimbursement, pricing, access and more. We look forward to having you be part of the event!


The two-day Congress will provide an interactive and intimate discussion and networking format led by key industry speakers with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies and concepts surrounding orphan drugs and rare diseases.


Gain Latest Insights On:


    • In-depth analysis of the orphan drugs markets
    • Focus on the existing and future trends
    • Highlights on the key growth and investments
    • Insights on key technological trends impacting the orphan drugs market
    • Understanding the roles of the key players and stakeholders
    • Learn the key economic drivers in the orphan market
    • The Roles of Big Pharmas, Biotechs and Start-Ups
    • What Strategies Are Available to Ensure Partnership Success
    • Clinical Trials: From Early Drug Development to Patient Recruitment and More
    • Pricing Strategy: How to Price Correctly?


Who you will meet


Presidents, Heads/Chiefs, Directors, VPs and Managers of:


  • Research and Development
  • Regenerative Medicine
  • External R&D Innovation
  • Immunology
  • Clinical Scientist
  • Gene Therapy
  • Translational Science
  • Molecular Geneticist
  • Program Management
  • Patient Advocacy and Public Affairs
  • Medical Affairs
  • Regulatory Affairs
  • Clinical Field Specialist
  • Sales and Marketing
  • Outcomes & Evidence
  • Commercial Development
  • Product Specialist
  • Global Strategic Services
  • Business Planning and Operations


Featuring Key Industry Experts


    • Omar Khwaja, MD PhD, Global Head of Rare Diseases, F. Hoffmann-La Roche
    • Dr. Tim Cote, Principal and CEO, Cote Orphan
    • Amit K. Sachdev, Executive VP, Chief Regulatory Officer and Chief of Staff to the CEO, Vertex
    • Dr. Ken Kengatharan, President & iCEO, Armetheon Inc.
    • Dr Will Maier, Chief Scientific Officer, MAPI Group
    • Kelly Franchetti, Vice President Global Patient Insights and Engagement, MAPI Group
    • Rory Graham, Senior Director EU regulatory Services, MAPI Group
    • Immo Zadezensky, Senior Director, Head US for Global Regulatory and Scientific Policy, EMD Serono, Inc
    • Christopher Gibson, Co-Founder and CEO, Recursion Pharmaceuticals
    • Dr. John P. Cooke, Chair, Department of Cardiovascular Sciences, Houston Methodist Research Institute
    • Eduardo Bruno Martins, MD, DPhil, Sr. VP, Liver & Infectious Diseases Drug Dev’t., Eiger BioPharmaceuticals
    • Matthias Bödding, Head Global Drug Safety Medicine, Merck
    • Carlos R. Camozzi, Group Chief Medical Officer (CMO), Simbec Orion
    • Anja Harmeier, Global Project Leader for Rare Diseases, F. Hoffmann-La Roche Ltd
    • Sandra Shpilberg, CEO, Seeker Health
    • Alastair MacDonald, Executive Director Real World & Late Phase, INC Research
    • Jason Cameron, Vice President, Global Supply Chain, Amicus Therapeutics UK Limited
    • Jas Khera, Managing Director, WEP Clinical
    • Amandip Sidhu, Senior EAP Director, WEP Clinical
    • James Radke, PhD, Vice President, Editorial, Rare Disease Report
    • Rajini Haraksingh, Vice President, Science 2.0, Rare Genomics Institute
    • Leone Atkinson, MD, PhD, Executive Director, Neuroscience Medical and Scientific Services, Covance
    • Mike Page, Executive Director, Global Regulatory Affairs Portfolio Products, Alexion Pharmaceuticals
    • Robert Derham, Co-Founder, CheckOrphan
    • Peter Milner, Chairman, Armetheon Inc
    • Michael Henderson, VP, Asset Acquisition, Strategy, and Operations, BridgeBio
    • Fabrice Chartier, Phd, Group Chief Operating Officer, Simbec Orion Group

Previous Conference Gallery

Paradigm Global Events